<DOC>
	<DOCNO>NCT01921140</DOCNO>
	<brief_summary>This 3 part study patient solid tumour . The purpose Part A measure amount olaparib breakdown product bloodstream 72 hour eat effect olaparib QT interval follow single oral dose olaparib tablet . Part B determine effect olaparib QT interval follow multiple oral dosing . Part C allow patient continued access olaparib tablet provide additional safety data collection .</brief_summary>
	<brief_title>To Determine Effect Food Pharmacokinetics Olaparib Effect Olaparib QT Interval Following Oral Dosing Tablet Formulation Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Inclusion criterion : For inclusion study , patient fulfil follow criterion : 1 . Provision write informed consent prior study specific procedure . 2 . Patients age great equal 18 year . 3 . Able eat highfat meal within 30minute period , provide study site . 4 . Histologically , appropriate , cytologically confirm malignant solid tumour refractory resistant standard therapy suitable effective standard therapy exist . 5 . Normal organ bone marrow function measure within 28 day prior administration investigational product ( IP ) define : Haemoglobin great equal 10.0 g/dL , blood transfusion previous 28 day . Absolute neutrophil count ( ANC ) great equal 1.5 x 109/L . White blood cell ( WBC ) great 3 x 109/L . Platelet count great equal 100 x 109/L . Total bilirubin less equal 1.5 x institutional upper limit normal ( ULN ) except case Gilbert 's disease . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) less equal 2.5 x institutional ULN unless liver metastasis present case must less equal 5 x ULN . Serum creatinine less equal 1.5 x institutional ULN . Serum potassium , sodium , magnesium calcium within institutional normal range . 6 . Calculated serum creatinine clearance great 50 mL/min ( use CockroftGault formula 24hour urine collection ) . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 . 8 . Patients must life expectancy great equal 16 week . 9 . Evidence nonchildbearing status woman childbearing potential , postmenopausal status : negative urine serum pregnancy test within 28 day study treatment , confirm prior treatment Day 1 first treatment period Part A. Postmenopausal define : Amenorrheic 1 year follow cessation exogenous hormonal treatment . Luteinising hormone follicle stimulate hormone level postmenopausal range woman 50 year age . Radiationinduced oophorectomy last menses great 1 year ago . Chemotherapyinduced menopause great 1 year interval since last menses . Surgical sterilisation ( bilateral oophorectomy hysterectomy ) . 10 . Patients willing able comply protocol duration study include undergoing treatment schedule visit examination . 11 . Patients must stable concomitant medication regimen ( exception electrolyte supplement ) , define change medication dose within 2 week prior start olaparib dose , except bisphosphonates , denosumab , corticosteroid , stable least 4 week prior start olaparib dosing . Exclusion criterion : 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff , agent , and/or staff study site ) . 2 . Previous enrolment present study . 3 . Participation another clinical study IP last 14 day ( long period depend defined characteristic agent use ) . 4 . Patients receive systemic chemotherapy radiotherapy ( except palliative reason ) within 2 week prior study treatment ( long period depend defined characteristic agent use ) . The patient receive stable dose bisphosphonates denosumab bone metastasis study long start least 4 week prior treatment . 5 . Patients receive receive inhibitor inducer CYP3A4 . 6 . Toxicities ( great equal CTCAE Grade 2 ) cause previous cancer therapy , exclude alopecia . 7 . Patients symptomatic uncontrolled brain metastasis . A scan confirm absence brain metastasis require . Patients asymptomatic brain metastasis symptomatic stable brain metastasis receive stable dose corticosteroid study long start least 4 week prior treatment . 8 . Major surgery within 2 week start study treatment patient must recover effect major surgery . 9 . Patients unable fast 14 hour . 10 . Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease , uncontrolled seizure , active , uncontrolled infection . Examples include , limited , uncontrolled ventricular arrhythmia , recent ( within 3 month ) myocardial infarction , uncontrolled major seizure disorder , unstable spinal cord compression , superior vena cava syndrome , extensive bilateral interstitial lung disease high resolution compute tomography ( HRCT ) scan , psychiatric disorder prohibits obtain informed consent . 11 . Patients history poorly control hypertension rest blood pressure ( BP ) great 150/100 mm Hg presence absence stable regimen hypertensive therapy . Measurements make patient rest supine minimum 5 minute . Two reading take 2 minute interval average . If first 2 diastolic reading differ 5 mm Hg , additional reading obtain average . 12 . Patients history heart failure leave ventricular dysfunction , patient require calcium channel blocker . 13 . Patients type I type II diabetes . 14 . Patients gastric , gastrooesophageal oesophageal cancer . 15 . Patients unable swallow orally administer medication patient gastrointestinal disorder significant gastrointestinal resection likely interfere absorption olaparib . 16 . Breastfeeding woman . 17 . Immunocompromised patient , eg , patient know serologically positive human immunodeficiency virus ( HIV ) . 18 . Patients know active hepatic disease ( ie , hepatitis B C ) . 19 . Patients know hypersensitivity olaparib excipients product . 20 . Mean QTc Fridericia 's correction ( QTcF ) great 470 m screen ECG history familial long QT syndrome : A marked baseline prolongation QT/QTc interval ( eg , repeated demonstration QTc interval great 470 m ) . A history additional risk factor Torsade de pointes ( eg , heart failure , hypokalaemia , family history long QT syndrome ) . 21 . The use concomitant medication prolong QT/QTc interval . 22 . Clinical judgment investigator patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oncology , cancer , tumour , neoplasm , anticancer drug , food , area curve , pharmacokinetics , olaparib , neoplasm , metabolite , QT interval effect</keyword>
</DOC>